Cart
sales@molnova.com
GP2-114
CAS No. 130783-39-0
GP2-114( —— )
Catalog No. M33602 CAS No. 130783-39-0
GP2-114 is a catecholamine motility mimetic that produces current-dependent cardiovascular effects when administered via transdermal iontophoresis and can be used to study coronary artery disease (CAD).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 1216 | In Stock |
|
| 10MG | 2109 | In Stock |
|
| 25MG | 4076 | In Stock |
|
| 50MG | 5385 | In Stock |
|
| 100MG | 7301 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGP2-114
-
NoteResearch use only, not for human use.
-
Brief DescriptionGP2-114 is a catecholamine motility mimetic that produces current-dependent cardiovascular effects when administered via transdermal iontophoresis and can be used to study coronary artery disease (CAD).
-
DescriptionGP2-114 (GP-2-114) produces current-dependent cardiovascular action when administered by transdermal iontophoresis.
-
In VitroA 50% mixture of the RR and RS distereoisomer forms of GP-2-128 (GP2-114) have the same pharmacologic profile as the pure RR distereoisomer.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number130783-39-0
-
Formula Weight344.4
-
Molecular FormulaC19H24N2O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(CNC(CCC1=CC=C(C(N)=O)C=C1)C)(O)C2=CC(O)=C(O)C=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Abou-Mohamed G, et al. J Cardiovasc Pharmacol. 1994 Mar;23(3):485-91. Integrative cardiovascular actions of a novel catecholamine, GP-2-128.?
molnova catalog
related products
-
AF64394
AF64394 is a selective inverse agonist of GPR3(pIC50 : 7.3).
-
PACAP (1-38), human,...
PACAP (1-38), a novel neuropeptide isolated from the bovine hypothalamus is more active than vasoactive intestinal peptide (VIP) in stimulating adenylate cyclase (EC50=7 nM). PACAP 1-38 (10-9 M) increased substance P (SP), gastrin releasing peptide (GRP), and VIP release. PACAP 1-38 (10-8 M) inhibited gastrin secretion and stimulated somatostatin secretion and motility dose-dependently.
-
R 715
R715 is a selective bradykinin B1 receptor antagonist. R715 significantly attenuates the hyperalgesic effect developed in Streptozotocin -diabetic mice.
